1999
DOI: 10.1002/(sici)1097-0142(19991115)86:10<2006::aid-cncr18>3.0.co;2-2
|View full text |Cite
|
Sign up to set email alerts
|

Fludarabine, cytarabine, and granulocyte-colony stimulating factor for the treatment of high risk myelodysplastic syndromes

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

1
6
0
1

Year Published

1999
1999
2012
2012

Publication Types

Select...
9
1

Relationship

3
7

Authors

Journals

citations
Cited by 24 publications
(8 citation statements)
references
References 25 publications
1
6
0
1
Order By: Relevance
“…The FLAG and FLAG‐idarubicin (Ida) regimens, which combine fludarabine (FDR), high dose cytosine arabinoside (ara‐C) and granulocyte colony stimulating factor (G‐CSF) with or without Ida, have recently been used with encouraging results in poor risk acute myeloid leukaemia (AML), MDS and refractory or relapsed acute lymphoblastic leukaemia (ALL) (Estey et al , 1994; Visani et al , 1994; Clavio et al , 1996; Nokes et al , 1997; Parker et al , 1997; Deane et al , 1998; Fleischhack et al , 1998; Montillo et al , 1998; Ferrara et al , 1999; Steinmetz et al , 1999; Jackson et al , 2001). The toxicity of this combination regimen was also found to be low.…”
mentioning
confidence: 99%
“…The FLAG and FLAG‐idarubicin (Ida) regimens, which combine fludarabine (FDR), high dose cytosine arabinoside (ara‐C) and granulocyte colony stimulating factor (G‐CSF) with or without Ida, have recently been used with encouraging results in poor risk acute myeloid leukaemia (AML), MDS and refractory or relapsed acute lymphoblastic leukaemia (ALL) (Estey et al , 1994; Visani et al , 1994; Clavio et al , 1996; Nokes et al , 1997; Parker et al , 1997; Deane et al , 1998; Fleischhack et al , 1998; Montillo et al , 1998; Ferrara et al , 1999; Steinmetz et al , 1999; Jackson et al , 2001). The toxicity of this combination regimen was also found to be low.…”
mentioning
confidence: 99%
“…The combination of fludarabine phosphate (FAMP) with intermediate-or high-dose cytarabine (ARA-C) and G-CSF (FLAG) has been proved to be a potentially useful chemotherapy regimen for poor prognosis AML, such as secondary or relapsing AML (8)(9)(10)(11), as well as for high-risk MDS (12,13). In addition, the FLAG regimen delivers high-dose treatment without increasing overall toxicity, an approach which is of particular interest in older patients (12,13). The therapeutic combination is based on the synergistic action of FAMP and ARA-C in increasing two-fold the intracellular concentration of the active ARA-C metabolite ARA-CTP (14).…”
mentioning
confidence: 99%
“…In this study, patients with secondary AML had been given a different induction with the FLAG regimen, therefore one could hypothesize that the worse outcome of this subgroup would depend on different induction therapy. However, FLAG in turn represents an effective therapeutic option for induction of CR in poor‐risk AML and MDS (Ferrara et al , 1999, 2002). In addition, all patients with secondary AML received IDA in the consolidation, suggesting that the poorer outcome was not related to different induction/consolidation therapy.…”
Section: Discussionmentioning
confidence: 99%